Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

IQST - IQSTEL and Cycurion - CYCU Execute $1 Million Stock Exchange, Announce Dividend Distribution and Strategic AI Cybersecurity Alliance

(NASDAQ:IQST) Shares will be calculated based on September 2, 2025, and planned to be issued within 30 days. Each company will distribute up to 50% of the received shares as a stock dividend, makin...

How does this AI-driven cybersecurity alliance position IQSTEL and Cycurion against industry competitors and affect future earnings forecasts? What are the potential tax and regulatory implications for shareholders receiving stock dividends in this transaction? How will the $1 million stock exchange and dividend distribution impact the price and volatility of IQST and CYCU shares?
Symbol: IQST
Mergers
11 days ago
Read more prnewswire

Blue Owl Technology Finance Corp. Announces Partial Early Lock-Up Release

(NYSE:OTF) NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Blue Owl Technology Finance Corp. (NYSE: OTF) ("OTF" or the "Company") today announced a partial early lock-up release on approximately 10% of eac...

Do the terms of this partial release suggest any changes to the company’s capital structure or future financing plans? What is the expected impact on the stock’s volatility and price trajectory after the September 9, 2025 release? How will the early lock‑up release affect the short‑term supply and demand dynamics for OTF's shares?
Symbol: OTF
Corporate
11 days ago
Read more prnewswire

AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

(NYSE:ABBV) Data presented at 13th Society of Hematologic Oncology (SOHO) Annual Meeting NORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from ...

How might the outpatient monitoring data influence market adoption, pricing strategy, and competitive positioning against existing DLBCL therapies? What is the expected timeline for regulatory submission and approval of epcoritamab in DLBCL compared to competitors’ pipelines? How will the updated Phase 2 results affect AbbVie’s near‑term revenue forecasts and valuation?
Symbol: ABBV
Clinical trials
11 days ago
Read more prnewswire